March 15, 2024Blood Cancer JournalOpen Access

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial finds lower non-relapse mortality and higher survival in MMUD alloSCT with PTCy, suggesting preference over rATG.

Lower non-relapse mortality was observed in the PTCy group at 18% compared to 24.9% in the rATG group, suggesting its efficacy.
Overall survival rates were higher in the PTCy group with 65.7% versus 55.7% in the rATG cohort after two years.
Analysis utilized multivariate methods on data from 2,123 patients undergoing peripheral blood alloSCT from mismatched unrelated donors (MMUD). These findings highlight the potential benefit of PTCy over rATG in reducing mortality after stem cell transplants.

Penack et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark